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Using comparative genomic hybridization (CGH), we have identified and mapped regions of DNA amplification in primary and 
metastatic osteosarcomas. Samples were obtained from four patients and ten independent xenografts. Sixty-four percent of the 
tumors showed increased DNA-sequence copy numbers, affecting 23 different chromosomal sites. Most of these regions were 
not previously associated with the development and/or progression of these tumors. Amplicons originating from I q2l-q23, 6p, 
8q23-qter, and I7p(l-pl2 were observed most frequently. The 6p and I7pl!-p(2 amplicons seem to be specific for 
osteosarcomas, indicating that these regions may harbor genes relevant for the development of these tumors. Genes Chromosom 
Cancer 14:15-21 (1995). © 1995 Wiley-Liss, Inc.
INTRODUCTION
Osteosarcoma is the most common malignant tu­
mor of bone in adolescents. Classical osteosarco­
mas are high-grade malignant tumors with a poor 
prognosis, and 1 0 - 2 0 % of the patients have detect­
able metastases at diagnosis. Little is known about 
the cytogenetic changes in these tumors, or how 
such alterations may relate to tumor initiation or 
progression. However, several reports have dem­
onstrated highly aneuploid and extremely complex 
karyotypes with numerous cytogenetic abnormali­
ties, including ring chromosomes and double min­
utes (Mertens et al., 1993; Tarkkanen et al., 1993; 
Fletcher et at., 1994; Sandberg and Bridge, 1994). 
T he  most frequent observations include loss of 
chromosomes 13 and 17 or of the 13q 14 and 17pl3 
bands (Hoogerwerf et al., 1994; Sandberg and 
Bridge, 1994).
Accordingly, the most important genetic alter­
ations in osteosarcomas may involve the tumor
suppressor genes TP53 (17pl3) and RBI (13ql4). 
Abnormalities of the TP53 gene— loss, rearrange­
ment, mutation, and deletion—have indeed been 
observed in a large fraction of the osteosarcomas 
studied (Miller et al., 1990; Mulligan et al., 1990; 
Andreassen et al., 1993). Other studies have shown 
that osteosarcomas frequently exhibit structural 
anomalies of the retinoblastoma gene RBI (To- 
guschida et al., 1988), and patients with hereditary 
retinoblastoma frequently develop osteosarcoma. 
It was recently shown that loss of heterozygosity 
(LOH) or other DNA alterations at the RBI locus 
in primary osteosarcoma are associated with a poor 
clinical outcome (Wadayama et al., 1994). Thus,
functional inactivation of these genes, by either 
dominant or recessive modes, could play a major 
role in the development of these cancers.
Recently, the protooncogene MDM2, which en­
codes a protein that binds to and probably inacti­
vates p53 (Momand et al., 1992; Oliner et al.,
1992), was found to be amplified in a number of 
sarcomas (Oliner et al., 1992; Forus et al., 1993; 
Ladanyi et a l ,  1993; Leach et al., 1993). In os­
teosarcomas, MDM2 amplification was detected in 
about 30% of recurrent and metastatic lesions, but 
not in primary tumors (Ladanyi et al., 1993), and it 
was suggested that MDM2 amplification may be 
associated with metastatic disease and concurrent 
poor prognosis. However, we detected no MDM2 
amplifications in our osteosarcoma panel, although 
more than one-third of the samples were obtained 
from metastatic lesions (Forus et al., 1993; Fl0 - 
renes et al., 1994). Clearly, our current knowledge 
of the occurrence, nature, and role of specific ge­
netic changes in the development and progression 
of these tumors is still far from complete.
Here we have applied comparative genomic hy­
bridization (CGH), a recently developed method 
to survey entire genomes for DNA-sequence copy 
number variations (Kallioniemi et al., 1992; Du 
Manoir et al., 1993; Suijkerbuijk et al.> 1994a), to 
elucidate some of these questions. In doing so, we 
were able to identify and map 23 regions of DNA 
amplification in 14 primary and metastatic human 
osteosarcomas.
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MATERIALS AND METHODS
Specimens
Tumor tissues were obtained from four patients 
with osteosarcoma (three primary and one meta­
static lesion) and from ten independent xenografts 
grown subcutaneously in nude mice. All the tu­
mors were highly malignant (grade IV). Seven of 
the xenografts were established from primary tu­
mors, the rest from metastatic lesions. The xe­
nografts have been passaged several times, and 
some of them have existed as xenograft lines for 
years. The tumor tissues were frozen in liquid ni­
trogen immediately after surgery and stored at 
-70°C. DNA isolated from blood from a healthy 
woman (46,XX) was used as reference.
Preparation of DNA
Genomic DNA from tumor tissues and periph­
eral blood cells was isolated by standard methods 
(Forus et al., 1993).
Comparative Genomic In Situ Hybridization
CGFI experiments and the evaluation of the re­
sults were performed as described previously 
(Forus et al., 1995). The analysis was based on 
visual assessment, followed by profile quantitation 
of the aberrant chromosomes,
RESULTS
DNA extracted from frozen tissue was used for 
CGH analysis. Based on the previously described 
criteria for interpretation of CGH results (Kallio- 
niemi et al., 1994b; Suijkerbuijk et al., 1994b; 
Forus et al., 1995), we detected regions of in­
creased DNA-sequence copy numbers in nine of 
the 14 (64%) primary and metastatic lesions exam­
ined. In Figure 1 , the chromosomal localization of 
the various amplicons is depicted. The regions in­
volved in each individual case are provided in Ta­
ble 1. As indicated, the size of the different ampl­
icons varied considerably, ranging from very small 
DNA segments to whole chromosome arms. Usu­
ally, multiple regions were amplified in a single 
specimen. Regions of interindividual variance 
(i.e., heterochromatic) and pericentrometric re­
gions were excluded from the analysis (Forus et al., 
1995).
In five cases (OS4x, OS5x, OS9x, O Sllx, and 
OS13x), CGH revealed gain of whole chromo­
somes or chromosome arms, and in three of these 
cases (OS5x, OS9x, and OSl3x), 6 p was involved 
(Fig. 2). In another sample (OS6 x), amplification 
of the 6pll-p21.2/21.3 region was revealed. Extra
16
copies of 5p and lOp were detected only once
(OS5x and OS9x).
Regional copy number increases were seen re-
w
peatedly at Iq21-q23, 8q23~8qter, and 1 7 p l l -  
pl2. T he  amplicons on lq  (OS4x, OS9x, and 
OS13x) were somewhat variable in size but showed 
a minimal region of overlap at Iq21-q23. T he  
8q23-8qter amplicon was observed in three cases 
(OS5x, O Sllx , and OS13x), including one showing 
gain of the whole 8 q arm (O Sllx ; Fig. 2). Ampli­
fication of 17p 11—pl2 was detected in a total of four 
cases (OS4x, OS5x, OS8 x, and OS21; Fig. 2), 
again including one with amplification of the whole 
17p arm (OS5x). In one sample (OS8 x), 17p 11—p 12 
was the only detectable amplicon. ,
Also, regions on 5q (OS9x and OS13x), 12q 
(OS6 x and OSllx), 15q (OS5x, O S llx , and OS21), 
and 17q (OS4x and OS5x), as well as other chro­
mosomal sites, showed copy-number increases. 
However, these latter anomalies occurred at rela­
tively low frequencies (in only one or two samples). 
Overall, the present CGH analysis revealed high- 
level DNA amplifications at 23 different chromo­
somal sites in primary as well as metastatic osteosa­
rcomas.
DISCUSSION
T he observations reported here significantly ex­
tend our current knowledge on the genetic alter­
ations that occur in human osteosarcomas. Previous 
molecular and cytogenetic analyses have demon­
strated the occurrence of nonrandom loss of chro­
mosome 13- and 17-derived regions during the de­
velopment of osteosarcomas (Miller et al., 1990; 
Andreassen et al., 1993; Mertens et al., 1993; Tark^- 
kanen et al., 1993; Fletcher et al., 1994; Sandberg 
and Bridge, 1994; Wadayama et al., 1994). How­
ever, most of the regional copy-number changes 
(amplicons) reported here were not detected pre­
viously, nor were any of them associated with the 
development and/or progression of these tumors.
Regions of increased DNA-sequence copy num­
bers were detected in primary as well as metastatic 
lesions, but our studies failed to show any overt 
correlation between the malignancy stage of indi­
vidual tumors and the number o'f amplified regions 
observed in them (Table 1). However, amplified 
regions were detected in a substantially larger frac­
tion of xenografts (eight of ten) than of primary 
tumors (one of four). Previous analyses of 1 2q 13— 
q l4  amplifications in a large panel of human sarco­
mas showed an equal distribution of such aberra­
tions among xenografts and primary samples (Forus 
et ah, 1993; Fl0 renes et al., 1994). Cases where
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Figure I. Chromosomal localization of DNA-sequence copy number increases in 14 osteosarcomas as 
detected by CGH. Only those chromosomes in which amplified regions were detected are represented. A 
vertical bar indicates an amplified region in a given tumor sample. The chromosomal band location of the 
amplicons was determined on the basis of DAPl banding pattern. Because high-resoiution subband localiza­
tion was not possible, the amplified regions may in fact be smaller than indicated.
both the xenograft and the primary sample were 
available consistently showed the same gene am- 
plification status both by Southern blot analysis 
(Forus et al., 1993) and by CGH analysis (MS8 / 
VMS8 x and LS28/LS28x; Forus et al., 1995). Ap­
parently, xenografting per se does not induce am­
plifications. However, xenografts are more easily 
established from aggressive tumors, which may be 
more likely to contain such aberrations.
T he  two samples (OS6 x and O Sllx ; Table 1 ) 
with previously detected amplifications of SAS  and 
CDK4 (Forus et al,, 1994) showed increased DNA- 
sequence copy numbers at 12ql4, as expected. 
Gains of sequences were also observed at the distal 
parts of 5q, 15q, and 17q. Although the amplifica­
tions at 15q were highly variable in size, they over­
lap at 15q22-q25 (OS5x and O Sllx ) and 15q26— 
qter (OS5x and OS21). Thus, important genes in
this context may be the protooncogenes F E S  and 
FUR at 15q25-qter (Donlon and Malcolm, 1991). 
There are no obvious candidate genes in the 5q22- 
q23-qter (OS9x and OS13x) and 17q24-q25 (OS4x 
and OS5x) regions (Solomon and Ledbetter, 1991; 
Washmut et al., 1991; Fain, 1992).
Gain of sequences from the long arm of chromo­
some 1 was detected in three of the 14 osteosarco­
mas (OS4x, OS9x, and OS13x; Table 1), with a 
minimal region of overlap at Iq21-q23. Amplifica­
tion of this segment ( Iq 2 1 ~q2 2 ) was detected also 
in 14/54 soft tissue sarcomas (Forus et al., 1995), 
indicating that sequences from this region may be 
related to the development of sarcomas in general, 
a possibility that has been discussed in more detail
by Forus et al. (1995).
Four cases showed amplification of 6 p se­
quences, with a minimal region of overlap at 6 p 1 1—
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TABLE \ . Distribution of Amplified Regions in i 4 Individual Osteosarcomas3
Tumors Regional copy-number gains Whole arms/chromosomes
Primary
OS2x 13q34
OS4x Iqf 1 —q23, 2qll-<j!2, 17pll-pl2, I7q24-q25 7, 14,22
OS5x 3pll-pí2, 8q23-qter, lOcen, 10q2l, 13q 13—q 14, 
!4cerMq2l, I4q23-qter, I5q22-qter, 17q24-25
6p, lOp, I7p
OS6x 4q34~qter, 6pll-2L2, 12ql4
OS7x
OS9x Ipl3-p31, Ip36, Iq2l-q25, 5q22-qter, 9q 1 3—q22 5p, 6p, 17
OSIIx 12q ! 4, I5q22-q25 8q
OS2lp 8p23, !5q26, I7pll-pl2
OS29p
OS3lp
Metastatic
OS8x !7pIl-pl2
OS!2x
OSI3x Ip36, Iq2l-q23, 5cen-pl4, 5q23-qter, 8q23-qter 6p
OSl7p
“Samples were obtained from primary material (p) and xenografts (x). The most frequently amplified regions are shown 
in boldface.
p21.3. The procooncogene PIMI at 6p21 (Ziegler 
et al., 1991) is a possible target gene. Amplification 
of 6 p has also been observed in breast cancer, al­
though at lower frequencies (Kallioniemi et al., 
1994a), and was detected only once in a panel of 
54 soft tissue sarcomas (Forus et al., 1995). Since 
this event seems to be more frequent in osteosar­
comas, it is possible that genes located in this 
region are involved in the development of these 
tumors.
The 8q23-qter amplicon was detected in three 
of 14 osteosarcomas (21%) and, most likely, in­
volves the MYC locus. Amplifications and other ab­
errations of the MYC oncogene have been observed 
in various neoplasms but were thought to be rela­
tively rare in osteosarcomas (Ladanyi et al., 1993). 
Our results indicate that MYC amplifications may 
be more frequent in our panel than in tumors an­
alyzed previously, although it cannot be excluded 
that genes other than MYC are responsible. Insofar 
as putative transcription factors are among the ma­
jor classes of oncogenes (Feldman and Yaar, 1991), 
the most interesting alternative candidates may be 
the two zinc-finger proteins ZNF7 and ZNF34 in 
band 8q24 (Donis-Keller and Buckle, 1991). It is 
conceivable that the target gene(s) of this amplicon 
plays a significant role(s) in a broader range of tu­
mors; the 8q24 band is known also to be amplified 
frequently in breast and prostate cancer (Cher et 
al., 1994; Kallioniemi et al., 1994a).
Increased copy number of sequences at 1 7 p l l -  
pl2 was detected in four of the 14 osteosarcomas 
(29%), Although regions distally in 17p appear to 
be frequently lost in this class of tumors (Miller et 
al., 1990; Mulligan et al., 1990; Andreassen et al,, 
1993; Fletcher et al., 1994; Sandberg and Bridge, 
1994), amplification of proximal 17p has not been 
reported previously. T h e  17p 1 1—pl2  amplicon was 
detected in only one of 54 soft tissue tumors (Forus 
et al., 1995).
Most of the proposed models for amplification 
(McCHntock, 1941; Toledo et al., 1992; Stark, 
1993) are based on asymmetric distribution of 
genes during cell division. It has'been suggested 
that mechanisms accounting for amplification will 
also lead to loss of heterozygosity (LOH; Stark,
1993). One might therefore speculate that the 
mechanism leading to increased copy numbers of 
the 1 7 p ll-p l2  segment is related to LO H  at the 
distal 17p region (e.g., of TP53). However, it is 
difficult to envisage how loss and gains in the same 
region could be simultaneously selected for. 
Among the tumors examined, LOH at the TP53 
locus was detected in the tumor with gain of the 
whole 17p arm (OS5x), and the remaining TP53 
allele was mutated (Andreassen et al., 1993). Data 
on the TP53 status were not available for the sam­
ples with 17pl 1—pl2  amplification (OS4x, OS8 x, 
and OS21), but LOH involving TP53 was found in 
other tumors without detectable gains of 17p re-
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f-igure 2. Image analysis of fluorescent D N A  from various osteosar­
comas (in red) and normal female reference D N A  (in green) hybridized 
co normal metaphase chromosomes. a~c (top): CGH analysis using D N A 
from OS9x (a), OS! Ix  (b), or OS2I (c). The amplicons on 6p (OS9x), 
8q (OS I Ix), and 17p I I - p i  2 (OS2I) are indicated by arrowheads. Mid­
dle panels: Isolated images of chromosomes 6 (a), 8 (b), and 17 (c). 
Lower panels: Integration of fluorescence intensity along the chromo­
somes depicted in the middle panels. The measured intensity profiles are
depicted by red (tumor D N A) and green (normal D N A ) lines. The blue 
lines represent the CGH profiles, i.e., the red-to-green ratio along the 
whole chromosome length. The peaks indicate the respective amplifica­
tions. d: Partial metaphase cell hybridized to D N A  from OS5x. e: DAPI 
banding pattern from the metaphase shown in d. Figure shows the 
amplifications on 3p I I —p 1, 6p, 8q23-qter, lOp.lOccn, !0q2 i, 17p, and 
17c|24 —q2S. Chromosomes with amplifications are indicated by their 
numbers (e).
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gions (OS12x and OS13x; Andreassen et al., 1993). 
We therefore conclude that LOH at 17pl3 and am­
plification of the 17p ll-p l2  region probably are 
independent events in the development of osteo­
sarcomas. So far, the 17pl 1—pl2 segment does not 
seem to harbor obvious candidate (onco)genes as 
drivers for these DNA amplifications. However, a 
number of (anonymous) reference markers previ­
ously mapped to this region (Solomon and Ledbet­
ter, 1991; Fain 1992) may be instrumental for po­
sitional cloning of putative target genes.
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NOTE ADDED IN PROOF
Among the tumors with amplification of 8 q, at 
least one was negative for MYC amplification, in­
dicating that other genes on 8 q may be responsible.
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